Kong W, Lu WJ, Dubey M, Suryawanshi RK, Vijayakumar S, Jeong Y, Gombar S, Diehn M, Shin K, Ott M, Chien YH, Sarin KY, Desai TJ, Beachy PA.
2025 Jun 3:S0092-8674(25)00562-8. doi: 10.1016/j.cell.2025.05.012. Epub ahead of print. PMID: 40494346.
Archives: Publications
Publications
A non-spike nucleocapsid R204P mutation in SARS-CoV-2 Omicron XEC enhances inflammation and pathogenicity
Tsujino S, Tsuda M, Ito J, Deguchi S, Taha TY, Nasser H, Wang L, Rosecrans J, Suzuki R, Suzuki S, Yoshimatsu K, Ott M; Genotype to Phenotype Japan (G2P-Japan) Consortium; Ikeda T, Takayama K, Sato K, Tanaka S, Tamura T, Fukuhara T.
2025 May 30:2025.05.28.656516. doi: 10.1101/2025.05.28.656516. PMID: 40502047; PMCID: PMC12154822.
Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus MPro inhibitors with potent in vivo efficacy
Detomasi TC, Degotte G, Huang S, Suryawanshi RK, Diallo A, Lizzadro L, Zapatero-Belinchón FJ, Taha TY, Li J, Richards AL, Hantz ER, Alam Z, Montano M, McCavitt-Malvido M, Gumpena R, Partridge JR, Correy GJ, Matsui Y, Charvat AF, Glenn IS, Rosecrans J, Revalde JL, Anderson D, Hultquist JF, Arkin MR, Neitz RJ, Swaney DL, Krogan NJ, Shoichet BK, Verba KA, Ott M, Renslo AR, Craik CS.
2025 Apr 25;11(17):eadt7836. doi: 10.1126/sciadv.adt7836. Epub 2025 Apr 23. PMID: 40267184; PMCID: PMC12017303.
Enhanced RNA replication and pathogenesis in recent SARS-CoV-2 variants harboring the L260F mutation in NSP6
Taha TY, Ezzatpour S, Hayashi JM, Ye C, Zapatero-Belinchón FJ, Rosecrans JA, Kimmerly GR, Chen IP, Walcott K, Kurianowicz A, Jorgens DM, Chaplin NR, Choi A, Buchholz DW, Sahler J, Hilt ZT, Imbiakha B, Vagi-Szmola C, Montano M, Stevenson E, Gordon M, Swaney DL, Krogan NJ, Whittaker GR, Martinez-Sobrido L, Aguilar HC, Ott M.
2025 Mar 31;21(3):e1013020. doi: 10.1371/journal.ppat.1013020. PMID: 40163530; PMCID: PMC11981139.
Torsional twist of the SARS-CoV and SARS-CoV-2 SUD-N and SUD-M domains
Rosas-Lemus M, Minasov G, Brunzelle JS, Taha TY, Lemak S, Yin S, Shuvalova L, Rosecrans J, Khanna K, Seifert HS, Savchenko A, Stogios PJ, Ott M, Satchell KJF.
2025 Mar;34(3):e70050. doi: 10.1002/pro.70050. PMID: 39969084; PMCID: PMC11837046.
Intracellular lipid droplets are exploited by Junín virus in a nucleoprotein-dependent process.
Vazquez CA, Escudero-Pérez B, Hayashi JM, Leon KE, Moreira JP, Castañeda Cataña MA, Groseth A, Ott M, Oestereich L, Muñoz-Fontela C, Garcia CC, Cordo SM.
2024 Oct 1;137(19):jcs261745. doi: 10.1242/jcs.261745. Epub 2024 Oct 14. PMID: 39292070.
Structure-based discovery of a highly bioavailable, covalent SARS-CoV-2 major protease inhibitor with pan-coronavirus activity and potent in vivo efficacy.
Detomasi TC, Degotte , Huang S, Suryawanshi RK, Diallo A, Lizzardo L, Zapatero-Belinchon FJ, Taha TY, Li J, Richards A, Hantz ER, Alam Z, Montano M, McCavitt-Malvido M, Gumpena R, Partridge JR, Correy GJ, Charvat AF, Glenn IS, Rosecrans J, Revalde JL, Anderson D, Hultquist JF, Arkin MR, Neitz J, Swaney DL, Krogan NJ, Shoichet BK, Verba KA, Ott M, Renslo AR, Craik CS.
[Preprint] 2025, January 18. 2025.01.16.633443; doi: https://doi.org/10.1101/2025.01.16.633443
The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2.
Suryawanshi RK, Jaishankar P, Correy GJ, Rachman MM, O’Leary PC, Taha TY, Zapatero-Belinchón FJ, McCavittMalvido M, Doruk YU, Stevens MGV, Diolaiti ME, Jogalekar MP, Richards AL, Montano M, Rosecrans J, Matthay M, Togo T, Gonciarz RL, Gopalkrishnan S, Neitz RJ, Krogan NJ, Swaney DL, Shoichet BK, Ott M, Renslo AR, Ashworth A, Fraser JS.
2024 Aug 29:2024.08.08.606661. doi: 10.1101/2024.08.08.606661. PMID: 39149230; PMCID: PMC11326214.
Enhanced RNA replication and pathogenesis in recent SARS-CoV-2 variants harboring the L260F mutation in NSP6.
Taha TY, Ezzatpour S, Hayashi J, Ye Chengjin, Zapatero-Belinchon FJ, ROsecrans JA, Kimmerly GR, Kimmerly GR, Chen IP, Walcott K, Kurianowicz, Jorgens DM, Chaplin NR, Choi A, Buchholz DW, Sahler J, Hilt ZT, Imbiakha B, Vagi-Szmola C, Montano M, Stevenson E, Gordon M, Swaney DL, Krogan NJ, Martinez-Sobrino L, Aguilar HC, Ott M.
[Preprint] 2024, December 30. 2024.12.30.628795; doi: https://doi.org/10.1101/2024.12.30.628795
Silencing the transcriptionally active HIV reservoir to improve treatment outcomes.
Prigann J, Tavora R, Furler O’Brien RL, Schulze-Gahmen U, Boehm D, Roan NR, Nixon DF, Ndhlovu LC, Valente S, Ott M.
2024 Oct;9(10):2470-2472. doi: 10.1038/s41564-024-01816-5. PMID: 39289508.